MorphoSys AG (LTS:0NDV)
€ 66.8 0 (0%) Market Cap: 2.55 Bil Enterprise Value: 2.50 Bil PE Ratio: 0 PB Ratio: 51.84 GF Score: 59/100

MorphoSys AG Investor Call Focused on Pelabresib Transcript

Jun 21, 2023 / 01:00PM GMT
Release Date Price: €27.44 (+1.18%)
Julia Neugebauer

Ladies and gentlemen, good morning and good afternoon. My name is Julia Neugebauer, Head of Investor Relations at MorphoSys. And it is my pleasure to welcome you to today's investor call that will focus on the potential of Pelabresib, our investigational BET inhibitor in myeloproliferative neoplasms.

Before we begin, I'd like to remind you on Slide 2 that some of our statements made during the call today are forward-looking statements, including statements regarding our expectations for the commercialization of our products and our development plans and expectations for the compounds in our pipeline. These forward-looking statements are subject to a number of risks and uncertainties that may cause our actual results to differ materially, including those described in MorphoSys 20-F and annual report, all for the year ended December 31, 2022, and from time to time in other SEC documents of MorphoSys. It is important to keep in mind that our statements on this webcast speak as of today.

I would now like to turn the call over to Jean-Paul Kress, our Chief Executive Officer. Jean

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot